Drug intelligence / Profile preview

Oulanti Weikang Tablet

Development stage
Unknown
Lead developer
Jiangxi Qingfeng Pharmaceutical
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Oulanti Weikang Tablet (欧兰替胃康片) is a proprietary Traditional Chinese Medicine (TCM) therapeutic developed by Jiangxi Qingfeng Pharmaceutical for the treatment of functional dyspepsia (FD). It is specifically indicated for the postprandial distress syndrome (PDS) subtype, which is characterized by symptoms such as postprandial fullness and early satiety, corresponding to the 'qi stagnation' pattern in TCM theory. As a Class 1.1 new Chinese medicine, it has undergone rigorous clinical testing in China, progressing from Phase II (CTR20191090) to Phase III (CTR20212643) clinical trials. The formulation is designed to regulate gastrointestinal motility and improve visceral sensitivity through a multi-component herbal approach.

Brand names
Oulanti Weikang TabletOulanti
Other names
欧兰替胃康片

Beyond the preview

Go deeper on Oulanti Weikang Tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oulanti Weikang Tablet.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call